GlassScriptPhysician profile
David Opai-Tetteh
NPI 1427077684
$18,888.24
in general payments reported to CMS, 2019-2025
33 companies · $2,319 in 2025
The $2,319 reported for 2025 was more than what 79% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,357 · 2020: $1,590 · 2021: $2,707 · 2022: $4,431 · 2023: $4,229 · 2024: $2,255 · 2025: $2,319.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,689 · Education: $114.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,688.87 |
| Education | $114.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $2,695.80 | 2019-2025 | Otezla, Otezla |
| Genzyme Corporation | $1,854.74 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $1,828.02 | 2019-2025 | |
| Janssen Biotech, INC. | $1,615.56 | 2019-2025 | Tremfya, Stelara, Simponi |
| Abbvie INC. | $1,535.62 | 2019-2023 | |
| Leo Pharma INC. | $1,251.26 | 2020-2025 | Adbry |
| Regeneron Healthcare Solutions, INC. | $1,110.31 | 2020-2024 | Dupixent |
| Sun Pharmaceutical Industries INC. | $1,029.88 | 2019-2025 | Winlevi, Absorica Ld, Ilumya |
| Ucb, INC. | $913.66 | 2019-2025 | Bimzelx, Cimzia |
| Pfizer INC. | $772.87 | 2019-2025 | |
| Lilly USA, LLC | $763.01 | 2019-2023 | Olumiant, Taltz |
| Incyte Corporation | $730.82 | 2021-2025 | Opzelura |
| Galderma Laboratories, L.P. | $723.25 | 2019-2025 | Nemluvio, Aklief |
| E.R. Squibb & Sons, L.L.C. | $517.19 | 2022-2024 | Sotyktu |
| Arcutis Biotherapeutics, INC. | $215.35 | 2023-2025 | Zoryve |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $203.95 | 2023-2024 | Vtama |
| Almirall LLC | $127.28 | 2019-2023 | Seysara |
| Celgene Corporation | $121.45 | 2019 | |
| Dermira, INC. | $109.72 | 2019-2021 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $99.58 | 2019-2025 | Jublia, Siliq, Cabtreo |
| Verrica Pharmaceuticals INC. | $96.86 | 2023-2025 | Ycanth |
| Botanix Sb INC | $84.96 | 2025 | Sofdra |
| Smith+Nephew, INC. | $81.96 | 2019-2021 | |
| Phadia US INC. | $69.22 | 2020-2023 | Immunocap |
| Paratek Pharmaceuticals, INC. | $62.69 | 2023-2025 | Nuzyra |
| Vyne Pharmaceuticals INC. | $54.24 | 2020-2021 | |
| Journey Medical Corporation | $50.54 | 2022-2023 | |
| Mayne Pharma Commercial LLC | $45.53 | 2019-2020 | |
| Organon LLC | $34.38 | 2025 | Vtama |
| Organogenesis INC. | $32.43 | 2024 | |
| Sandoz INC. | $22.46 | 2024 | Hyrimoz |
| Glenmark Therapeutics INC. | $19.00 | 2019 | |
| Epi Health, LLC | $14.65 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Opai-Tetteh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.